1. Annual report on the agreed workplan

Describe progress made on the agreed workplan. For each activity, detail (1) the actions taken, (2) the outputs delivered, as well as (3) any difficulties that may have been encountered. Three responses are expected. [maximum 200 words per activity]. Indicate, if an activity has been completed previously, has not yet started or has been placed on hold.

Activity 1

Title: Development of an International Anti-Hepatitis E Reference Panel

Description: The diagnosis of HEV requires a variety of tests including the detection of IgM and IgG antibodies. Analysis of IgM antibodies is particularly useful for the confirmation of acute infection. Anti-HEV IgG may also be detectable during acute infection. Anti-HEV IgG is also a marker of past HEV infection and seroprevalence and anti-HEV and indication of previous exposure of different populations to HEV infection. Anti-HEV IgG assays vary in their performance and different studies have given widely different estimates of the seroprevalence of anti-HEV.

The importance of reference materials for the diagnosis of HEV infections was discussed at the WHO Expert Committee for Biological Standardization which asked for and also endorsed this important project. Despite the establishment of an interim WHO International Reference Reagent (IRR, NIBSC code number 95/584) for antibodies to HEV in 1997, there are still wide discrepancies in the performance of anti-HEV assays. It was noted by the ECBS, at the time of establishment of the IRR that assays for anti-HEV were at an early stage of development and acknowledged that full assessment of new antibody assays requires panels of sera. Since the IRR was established, no international agreed unitage has been assigned to the preparation. In the original collaborative study, seven laboratories evaluated a range of mainly in-house developed assays and two commercial assays available at the time.

Fifteen years later, diagnostic sensitivities and specificities as well as inter-assay agreement have been shown to vary widely for different kits for the detection of both anti-HEV IgM and IgG. Anti-HEV IgM is the major serological marker of acute or recent HEV infection; however, the main problem with detection of this marker is specificity; this is further compounded by a lack of sensitivity. Significant underestimations of seroprevalence of HEV (IgG) have been the result of lack of sensitivity of available assays. These assay issues, compounded by the failure of many clinical diagnostic laboratories to test for HEV infection as an alternative diagnosis of acute hepatitis, have impacted on the surveillance of incident hepatitis E and understanding the extent of asymptomatic infection.

Different collaborators are already involved in the collection and preliminary testing of NAT-confirmed cases of hepatitis E – with genotype confirmation, and subsequent collection of sera/plasma samples prior to formulation of the panel and evaluation in an international collaborative study alongside the IRR. It may be possible to assign an internationally agreed unitage to the IRR.
Status: ongoing
The project was endorsed by the WHO Expert Committee on Biological Standardization (ECBS) in October 2015. Materials have been collected and characterized by the Paul-Ehrlich-Institut (PEI); the National Institute for Biological Standards and Control (NIBSC, UK) has been approached to continue with the project.

The activity is led by Dr Sally Baylis.

Activity 2
Title: Development of the 1st International Chikungunya virus reference reagent for serology
Description: The mosquito-borne Chikungunya virus (CHIKV) is a member of the Alphavirus genus in the Togaviridae family. Chikungunya was first identified in Tanzania in the early 1950s. The disease occurs not only in Africa but also in Asia and the Indian subcontinent and, since 2013, has spread to the Americas, particularly central and Southern areas. Small outbreaks have also occurred recently in Europe.

The diagnosis of Chikungunya requires a variety of tests including detection of IgM and IgG antibodies. Co-circulation of Chikungunya virus with Dengue virus (DENV) and Zika virus (ZIKV) frequently occurs and infections cause by these viruses share common signs and symptoms in infected patients. Accurate diagnosis and discrimination of CHIKV from other virus infections is important for patient care. Analysis of IgM antibodies is particularly useful for the confirmation of acute infection. Anti-CHIKV IgG may also be detectable during acute infection. Anti-CHIKV IgG is also a marker of past CHIKV infection and seroprevalence and anti-CHIKV and indication previous exposure of different populations to CHIKV infection.


Status: ongoing
The proposal to establish a reference reagent was endorsed by the WHO ECBS in October 2016.
The materials for the WHO collaborative study were distributed to participating laboratories in 2019. Results have been returned to PEI and analysis of the data has commenced. Due to the SARS-CoV-2 pandemic the evaluation had to be postponed. Submission to ECBS is planned for the meeting in March 2022.

The activity is led by Dr Sally Baylis.

Activity 3
Title: Development of the 1st International Standard for Chikungunya Virus (CHIKV) RNA for NAT-based Description: Chikungunya virus is a blood borne pathogen transmissible by mosquitoes that has the potential to be transmitted by blood transfusion. The availability of an international standard for Chikungunya virus RNA would facilitate the development and quality control of new NAT assays for use in blood donor screening and in medical diagnostic testing. Such assays would significantly improve the safety of the blood supply worldwide. The topic was assigned high priority by the ECBS, and WHO was requested to provide these materials as soon as possible.

The International Standard for Chikungunya virus RNA will be used as a global standard for the development of assays for the detection of Chikungunya infections in blood donors. It may also be used as a reference standard to evaluate the performance of assays for detection of Chikungunya viral RNA. Users will be blood donor screening and diagnostic test developers, blood banks, hospitals, clinical laboratories and other establishments performing Chikungunya testing.

Status: ongoing
The candidate international standard (IS) was established by WHO ECBS in October 2017 as the 1st IS for CHIKV RNA for NAT-based assays with an assigned unitage of 2.5 million International Units (IU)/mL. Stability studies are ongoing and indicate that the preparation is stable and suitable for long-term use.

The activity is led by Dr Julia Kress.

Activity 4
Title: Development of the 1st International anti-HCMV IgG Standard

Description: Human Cytomegalovirus (HCMV) is spread worldwide with prevalence between 40% and 100%. The virus causes relatively mild and asymptomatic infections in immune competent persons, but can cause congenital disease and severe complications in those with immunodeficiency, e.g. immunological immaturity; acquired immunodeficiency or immunosuppression. Diagnostics of HCMV specific IgG and IgM antibodies and IgG avidity play a major role in prenatal care, blood transfusions and especially transplantation medicine. Current anti-HCMV assays differ considerably in their sensitivity, and there is no international reference material available at the moment. PEI anti-HCMV-IgG reference material has been available since 1982, which is frequently requested by manufacturers for calibration of their anti-CMV test kits. But this material is of limited supply and is weakly positive and not defined in international units. The proposed standard may serve for the calibration of the manufacturer’s diagnostic kits, for quality control by competent authorities, and by users. WHO Expert Committee for Biological Standardization discussed the need for an international Standard expressed in IU/ml and endorsed the project.

In 2012 samples were sourced by PEI and tested for suitability for a possible candidate material as well as possible accompanying study samples selected. In April 2013 the project was shown to the WHO Collaborating Centre’s meeting and the proposal provided to the ECBS was adopted in October 2013. A Collaborative Study was carried out between 2014 and 2016 to establish the candidate standard. Overall, a candidate anti-CMV IgG standard was developed with an assigned unitage of 46.4 units per mL and vial. In view of the variety of the anti-CMV tests, and their currently non-comparative performance, it is expected that the candidate standard will significantly facilitate comparability between the tests and make the results more reliable.

Status: ongoing

The 1st WHO International Standard for CMV IgG antibodies was adopted by the ECBS in October 2017. The standard is available from PEI (code 136616/17), with 46.4 International Units per mL assigned.

Stability studies are ongoing.

The activity is led by Dr Heinrich Scheiblauer.

Activity 5

Title: Extension of the WHO repository for Transfusion Relevant Bacteria Strains - Validation study for Red Blood Cell Relevant Reference Strains

Description: Bacterial contamination of blood components is one of the major threats in transfusion medicine. WHO has been approached by international organisations in the blood field to improve the situation of contamination testing by provision of international reference materials. The WHO Expert Committee for Biological Standardization discussed this issue and endorsed the project of bacteria repository and its expansion.

As a first milestone four Platelet Transfusion Relevant Bacteria Strains were validated in an international study and established in 2010 as the 1st WHO Repository of Platelet Transfusion Relevant Bacterial Reference Strains. The proposal to enlarge the repository was also endorsed by WHO ECBS in 2010. The report of the collaborative study was sent to WHO ECBS for endorsement/adoption at the ECBS Meeting in Geneva in October 2015.

In line with the strategy to establish Relevant Bacterial Reference Strains for all blood components and ATMPs the next step will be to establish a bacterial panel for Red Blood Cells (RBC).

The proposed list includes strains of the following transfusion relevant bacterial species:
- Gram-positives: Bacillus cereus, Bacillus subtilis, Staphylococcus aureus, Micrococcus luteus, Streptococcus pyogenes
As strains from the already established bacterial repository for platelets fail to grow in red blood cell (RBC) concentrates due to their cold storage conditions, additional transfusion-related isolates were pretested for their growth properties in RBC respectively. In 2017/18, candidate material of the successful strains Listeria monocytogenes PEI-A-199, Serratia marcescens PEI-B-P-56, Serratia liquefaciens PEIA-184, Pseudomonas fluorescens PEI-B-P-77, Yersinia enterocolitica PEI-A-105 and Yersinia enterocolitica PEIA-176 was tested in a collaborative study. The analysis of the results revealed that, except for S. marcescens, all strains showed good to excellent and reliable growth in RBC units. Results were presented to ECBS and the first WHO International Reference Repository of Red Blood Cell Transfusion Relevant Bacterial Reference Strains was adopted in October 2019.

The activity is led by Dr Oleg Krut and Dr Marcel Prax.

**Activity 6**

**Title:** Participation in the Blood Regulators Network (BRN)

**Description:** WHO recognized the need for rapid and reliable external advice in the field of blood and blood safety. The BRN is a working group of seven leading regulatory authorities in the field of blood products with the task of reacting rapidly to emerging risks, assessing new technologies, and providing advice to WHO. Current topics are support to continuous implementation of Resolution WHA63.12 and the BRN document “Assessment Criteria for National Blood Regulatory Systems”; ongoing revision of the existing WHO NRA (national regulatory agency) assessment tools to include the WHO assessment criteria for blood regulatory systems; BRN supports requests for assessment of blood regulatory systems, e.g. in the African region (ICDRA 2017 recommendation); evaluation of new developments such as pathogen inactivation technology for blood components, storage of red blood cells; discussion of opportunities for international convergence of regulations; proposed guidelines on recombinant DNA derived biotherapeutics; results of EBoV (Ebola Virus) clinical trials using convalescent plasma performed in Guinea; and discussions on national decision making on the MSM deferral (e.g. US FDA, impact of ART).

**Status:** completed

The BRN, a working group of seven leading regulatory authorities in the field of blood products with the task of reacting rapidly to emerging risks, assessing new technologies, and providing advice related to blood and blood regulation aspects to WHO, was established upon recommendation of the ECBS in 2006.

By the end of 2020 the WHO terminated collaboration with BRN and founded a new group with new tasks. Following the initiation of the WHO action plan on blood WHO decided to establish a technical advisory group on blood regulation, availability and safety AG-BRAS. WHO appointed Dr Anneliese Hilger, PEI, to be the new chair of AG-BRAS which comprises 25 international experts in the field of blood.

**Activity 7**

**Title:** Support for the project “Improving Access to Safe Blood Products through Local Production and Technology Transfer in Blood Establishments” (“Achilles Project”)

**Description:** WHO undertakes the project to enable LMICs to make use of blood components currently discarded as biological waste. “Improving access to medical products through local production and technology transfer” should increase access, especially for the poor in developing and least developed countries to medicines, vaccines and diagnostics of importance to public health, and especially for neglected diseases of the type II and type III categories as well as the specific needs of developing countries in relation to type I diseases.

The project was started with the workshop “Improving Access to Safe Blood Products in Low- and Middle-Income Countries (LMIC): A Framework to improve Public Health” at WHO Headquarters, Geneva, 14-15 June 2012. The initiative is an important element in the implementation of Resolution WHA63.12, which has been supported also by the WHO BRN, e.g. by elaborating the document “Assessment Criteria for National Blood Regulatory Systems”.

PEI experts/inspectors will contribute by facilitating meetings and training courses in several regions of the world.
A WHO White Paper on “Increasing supplies of plasma-derived medicinal products in low- and middle-income countries through fractionation of domestic plasma” for revival of the Achilles project was written (Feb-Jul 2020), with PEI (Micha Nübling) being represented in the core drafting group. This document is expected to convince policy makers on the key steps to be taken to enable use of recovered plasma as valuable source for life saving medicines. Furthermore, funding organizations will be approached to invest in the Achilles project performed by WHO. Webinars on different aspects raised in the White Paper are in preparation, to be held in autumn 2021 in close cooperation with the ISBT WP on Global Blood Safety.

Under the umbrella of the GHPP “BloodTrain” project (Global Health Protection Programme, initiated by the German Ministry of Health), several activities related to Achilles project were initiated and followed, e.g.: supporting the instalment and the activities of the African Blood Regulators Forum, together with the partners WHO and NEPAD-AMRH (New Partnership for Africa’s Development – African Medicines Regulatory Harmonization); several trainings and workshops in the blood regulatory field were organized by PEI for regulators from African partner agencies.

2. Annual report on other activities requested

Should WHO have requested activities in addition to the agreed workplan, please describe related actions taken by your institution [maximum 200 words]. Please do not include in this report any activity done by your institution that was not requested by and agreed with WHO.

2.1 71st Meeting of the Expert Committee on Biological Standardization (ECBS), Geneva, Switzerland, (virtual meeting), 24-28 Aug. 2020
The President of the PEI, Professor Cichutek, acted as chairperson of the ECBS (Plenary/Vaccines Track). Dr Micha Nübling participated in the meeting.
The virtual meeting focused on issues of the SARS-CoV-2 pandemic.
The entire activities of the ECBS August 2020 are laid down in the WHO Technical Report Series (TRS 1028).

2.2 72nd Meeting of the Expert Committee on Biological Standardization (ECBS), Geneva, Switzerland, (virtual meeting), 19-23 Oct. 2020
The President of the PEI, Professor Cichutek, acted as chairperson of the ECBS (Plenary/Vaccines Track). Dr Anneliese Hilger, Dr Micha Nübling, Dr Jens Reinhardt, and Dr Gabriele Unger participated in the meeting.

2.3 73rd Meeting of the Expert Committee on Biological Standardization (ECBS), Geneva, Switzerland, (virtual meeting), 9-10 Dec. 2020
The President of the PEI, Professor Cichutek, acted as chairperson of the ECBS (Plenary/Vaccines Track). Dr Micha Nübling and Dr Gabriele Unger participated in the meeting.
The entire activities of the 72nd and 73rd ECBS 2020 are laid down in the WHO Technical Report Series (TRS 1030).

2.4 WHO Live Webinar on “Strengthening Blood Systems Through Effective Blood Regulation”, 3-6 Aug. 2020
Ms Joanna Atemnkeng, Dr Kristina Heinrich, Dr Anneliese Hilger, Mr Chancelar Kafere, Dr Herbert Mbunkah, Dr Micha Nübling, Dr Jens Reinhardt, and Mr Washington Samukange, participated in the meeting and gave presentations on the ‘Global Benchmarking Tool + Blood’ (GBT + Blood), as well as on criteria for blood establishments and regulatory requirements for IVDs.

2.5 WHO “Haemovigilance Training Workshop Live Webinar”, 20-23 Oct. 2020
Ms Joanna Atemnkeng, Dr Kristina Heinrich, Mr Chancelar Kafere, Dr Herbert Mbunkah, and Mr Washington Samukange, participated in the meeting and gave presentations on aspects of haemovigilance. Ms Joanna Atemnkeng also provided translation from English to French.

2.6 WHO Workshop on GBT + Blood, 19 Apr. 2021
Ms Joanna Atemnkeng, Dr Kristina Heinrich, and Mr Washington Samukange, participated in the meeting and gave presentations on aspects of the implementation of indicators for blood regulation into the GBT and the use of the GBT + Blood.
2.7 Cooperation with WHO in the area of WHO’s Prequalification Programme (PQ) for in vitro Diagnostic Devices (IVDs) and Procurement of IVDs
Experts from PEI IVD Laboratories and GHPP continued to participate in the WHO Prequalification of Diagnostics (PQDx) programme.

2.7.1 WHO criteria for Emergency Use Listing (EUL) of IVDs for the Diagnosis of SARS-CoV-2
Dr Heiner Scheiblauer participated in the drafting of WHO criteria for Emergency Use Listing of IVDs Detecting Antibodies to SARS-CoV-2 Virus (1 Jul. 2020) and SARS-CoV-2 Antigen Tests for Self Testing, for the quick launch by manufacturers.

2.7.2 Review of product dossier submissions and on-site audits of in vitro diagnostic devices (IVDs) for the WHO Prequalification Programme (PQDx)
Section Molecular Virology regularly supports WHO in product dossier assessments for the prequalification of nucleic acid amplification technique (NAT)-based IVDs. In the reporting period, four change requests were assessed for ten HXV NAT products.
In addition, two technical dossiers of HIV (antigen) self-tests have been assessed as part of the regular WHO prequalification programme as is now routine practice between WHO and PEI-IVD Testing Laboratory. Against the background of the Covid-19 pandemic, four dossier reviews for SARS-CoV-2 NAT assays were performed within the WHO Emergency Use Listing procedure, one by Section Molecular Virology and three with support by GHPP colleagues formerly trained by WHO IVD PQ Unit in IVD assessment (H. Mbunkah, C. Kafere) under supervision by the head of the Collaborating Centre (M. Nübling).

2.8 Support of WHO by Mr Washington Samukange (GHPP) in the following areas:
• work on GBT + Medical Devices (teleconferences);
• drafting of the WHO Guideline on Testing and Processing (final draft August 2020);
• technical committee on haemovigilance tools (telephoneconferences).

2.9 International Nonproprietary Names (INN) of blood products and monoclonal antibodies
From July 2020 to June 2021, Dr Weisser assessed 238 INN requests of biological and 205 INN requests of chemical substances. She attended two WebEx-consultations of the INN expert group (71st consultation, October 2020; 72nd consultation, April 2021), where new and outstanding applications were discussed and decisions on the selection of INNs were taken. She was head of a working group on the naming scheme for monoclonal antibodies, which met twice via WebEx during that period.

3. Resources
Indicate staff time spent on the implementation of activities agreed with WHO (i.e. those mentioned in questions no. 1 and no. 2 above). Do not include any data related to other activities done by your institution without the agreement of WHO. Please indicate staff time using the number of “full-day equivalents” – a day of work comprising 8 hours (e.g. 4 hours work per day for 7 days should be recorded as 3.5 full-day equivalents).

Number of staff involved (either partially or fully)

<table>
<thead>
<tr>
<th>Senior staff</th>
<th>Mid-career staff</th>
<th>Junior staff, PhD students</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Number of full-day equivalents, total for all staff involved

<table>
<thead>
<tr>
<th>Senior staff</th>
<th>Mid-career staff</th>
<th>Junior staff, PhD students</th>
</tr>
</thead>
<tbody>
<tr>
<td>293</td>
<td>261</td>
<td>0</td>
</tr>
</tbody>
</table>
Implementation of the agreed workplan activities (i.e. those mentioned in questions no. 1 and no. 2 above) normally require resources beyond staff-time, such as the use of laboratory facilities, purchasing of materials, travel, etc. Please estimate the costs of these other resources as a percentage of the total costs incurred (e.g. if you incurred costs of USD 100 and the value of your staff time was USD 50 which makes the total of USD 150, please report 33.3% and 66.7%).

<table>
<thead>
<tr>
<th>Percentage of costs associated with staff time</th>
<th>Percentage of costs associated with other resources</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>75.00</td>
<td>25.00</td>
<td>100.00</td>
</tr>
</tbody>
</table>

4. Networking

Describe any interactions or collaboration with other WHO Collaborating Centres in the context of the implementation of the agreed activities. If you are part of a network of WHO Collaborating Centres, please also mention the name of the network and describe your involvement in that network [maximum 200 words].

4.1 (WebEx) Meetings of WHO Collaborating Centres (CC) to support the development of WHO Biological Reference Preparations for Blood Products and in vitro Diagnostic Devices

Due to the SARS-CoV-2 pandemic, no meetings of WHO Collaborating Centres (CC) network took place in the reporting period.

4.2 Participation in WHO Collaborative Studies for IVD

4.2.1 Participation in the WHO Collaborative Studies for Establishment of the 1st WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin as well as the 1st WHO International Reference Panel for Anti-SARS-CoV-2 Immunoglobulin

The studies were led by NIBSC, PEI participation by Dr Angela Filomena, PEI-IVD Testing Laboratory and Dr Barbara Schnierle, Unit AIDS, New and Emerging Pathogens.

4.2.2 Participation in the pilot project for selection of samples for the first WHO International Standard for SARS-CoV-2 Antigen

Led by NIBSC, PEI participation by Dr Heinrich Scheiblauer.

4.3 Participation in WHO Collaborative Studies for blood products

In 2020, PEI Section Batch Release of Blood Products, Logistics, Division Haematology participated in the collaborative studies to establish the 3rd WHO International Standard (IS) for Thrombin (established by WHO ECBS in August 2020) and the 3rd WHO IS for von Willebrand factor concentrate (adoption by WHO ECBS still pending). Both studies were organized by NIBSC, UK.